Vorinistat (Zolinza) failed to extend survival as a second-line therapy in patients with advanced mesothelioma according to results from a recent Phase III trial of over 660 patients, thought to be the largest ever of its kind in malignant pleural mesothelioma.
Vorinistat, a histone deacetylase inhibitor that works by altering gene expression and protein activity, failed to meet its primary endpoint of lengthening overall survival in patients who had failed prior chemotherapy.
Lee Krug, MD, of Memorial Sloan-Kettering Cancer Center in New York and colleagues reported their findings at the European Multidisciplinary Cancer Congress (EMCC) this week.
This trial was known as the VANTAGE014 study. There is no standard second-line chemotherapy for patients who fail standard first-line therapy (first-line therapy being pemetrexed + either cisplatin or carboplatin). Thus in the trial patients were randomized to receive either:
A. Best supportive care + vorinostat
B. Best supportive care + placebo.
About 2500 people in the US are diagnosed with this form of lung cancer annually, and median survival time from diagnosis is around 12 months.
Source
Krug LM, et al. "Vorinostat in patients with advanced malignant pleural mesothelioma who have failed prior pemetrexed and either cisplatin or carboplatin therapy: A phase III, randomized, double-blind, placebo-controlled trial." ECCO-ESMO 2011; Abstract 3BA.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
